Anika Therapeutics, Inc. (ANIK): M&A transaction — Anika Therapeutics completes sale of Arthrosurface for $10M; plans to divest Parcus Medical

Anika Therapeutics, Inc.

Sold Arthrosurface to Phoenix Brio for $7M note plus up to $3M contingent consideration based on sales performance.
Announced intention to sell Parcus Medical sports medicine business as part of strategic review.
Focus shifts to core hyaluronic acid (HA) products and Regenerative Solutions, targeting $4B global market.
Piper Sandler serving as exclusive financial advisor for both the Arthrosurface sale and potential Parcus divestiture.

Key facts

Extracted from this filing and checked against the source text.

M&A Transactions SEC 8-K Item 2.01/5.01 confidence 0.95

Anika Therapeutics, Inc. completed a disposition involving Phoenix Brio, Incorporated for ten-year non-interest bearing promissory note in the principal amount of $7,000,000 (closed 2024-10-31).

Action: disposition
Counterparty: Phoenix Brio, Incorporated
Consideration: ten-year non-interest bearing promissory note in the principal amount of $7,000,000
Closing: 2024-10-31

Exact text from the filing

“Transaction”). As consideration for the Transaction, at closing, the Buyer delivered to the Company a ten-year non-interest bearing promissory note in the principal amount of $7,000,000. Under the terms of the Purchase Agreement, the Company is also eligible to receive: (i) for each calendar quarter, an amount equal to a percentage of the net sales (the “Revenue

View on SEC.gov

Browse all m&a transactions →

Anika Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001171843-24-005922

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.